Le Lézard
Classified in: Health, Science and technology
Subject: ANNUAL MEETINGS

Acerus Announces Voting Results for the 2022 Annual Meeting


TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation ("Acerus") (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on June 27, 2022. The total number of shares represented in person or by proxy at the meeting was 6,923,589, representing 89.83% of the total issued and outstanding Acerus shares.

Election of Directors

The seven (7) candidates nominated for election to the Acerus board of directors and listed in Acerus' management information circular dated May 9, 2022, were elected by a majority of the votes cast by shareholders present in person or represented by proxy at the meeting. The voting results are as follows:

NameVotes For (%)Votes Withheld (%)
Ian O. Ihnatowycz6,895,681 (99.85%)10,296 (0.15%)
Geoff Cotton6,892,290 (99.80%)13,687 (0.20%)
Borys Chabursky6,894,424 (99.83%)11,553 (0.17%)
Stephen Gregory6,894,576 (99.84%)11,401 (0.17%)
Samuel Herschkowitz6,895,878 (99.85%)10,099 (0.15%)
Scott Leckie6,893,526 (99.82%)12,451 (0.18%)
Edward Gudaitis6,895,731 (99.85%)10,246 (0.15%)
   

Appointment of Auditors

Acerus announced today that its shareholders have approved the re?appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the fields of urology and men's health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus' shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice regarding forward?looking statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 14, 2022 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Company Contact
[email protected]

Investor Relations Contact
Chris Witty
Acerus Investor Relations
(646) 438-9385
[email protected]



These press releases may also interest you

at 21:30
The demand for mobile point-of-sale (mPOS)...

at 21:05
BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound...

at 21:00
LG Electronics USA announced today the 2022 lineup of TONE Free® true wireless earbuds. The new models provide the ultimate sound experience with advanced audio technologies, a better-fitting design, and a host of useful, new features. The new TONE...

at 20:30
On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA"). Malignant glioma has...

at 20:10
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFN? in a...

at 20:00
NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan's Food and Drug Administration (TFDA) in July 2022, and is planned for submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022....



News published on 27 june 2022 at 17:30 and distributed by: